KRAS and esophageal cancer: Druggable target: Some of the ongoing clinical trials examine LY4066434, a Pan-KRAS inhibitor (phase 1, NCT06607185) for advanced solid tumors [131], as well as BI 3706674 (phase 1, NCT06056024) in patients with gastric or esophageal cancer that present KRAS amplification [132].